Sartorius Stedim Biotech Release: New Webinar On Developing Process Workflows For Rapid Scale-Up
With a Case Study from WuXi Biologics Detailing the Advantages of Integrating Bioreactor Models with Single-use Production Scale Bioreactors
Cambridge, UK – September 28, 2016: Sartorius Stedim Biotech (SSB) today announced that it is co-presenting a new bioprocess webinar with WuXi Biologics, a premier Contract Discovery, Development and Manufacturing Organization, on Thursday 20th October. Two live events (at 09.00 GMT and 15.00 GMT) will include detail how WuXi Biologics is using ambr® micro and mini bioreactor platforms to accelerate bioprocess development of biologics in production scale single-use bioreactors.
During the live one-hour webinar, Dr Barney Zoro, ambr 15 Product Manager at SSB, will provide a brief overview of the ambr® 15 cell culture and ambr® 250 high throughput bioreactor systems and will explain how these can integrate seamlessly with the single-use BIOSTAT® STR manufacturing scale single-use bioreactors.
Dr Jincai Li, Vice-President at Wuxi Biologics, will detail their new single-use bioprocess development workflow. He will highlight how the ambr 15 system delivers better clone selection and feeding/product quality studies, as well as powerful Design of Experiment (DoE) optimization. Dr Li will also discuss how the ambr 250 high throughput system demonstrates excellent correlation to benchtop bioreactors with viable cell counts, titers and metabolite profiles, and will show how the ambr platforms are helping Wuxi Biologics’ scientists reduce time-lines when scaling up their bioprocesses into single-use bioreactors.
To join the webinar and receive a recording to listen to on-demand, scientists should register at: http://view6.workcast.net/register?cpak=2367672989355948
Dr Barney Zoro, ambr 15 Product Manager, at SSB commented: "I am pleased to be presenting a webinar with Dr Li, where he will show data on how WuXi Biologics’ new workflow supports increased experimental capacity to reduce timelines.”
Zoro added: “Scientists wanting to improve clone selection and accurately predict scale-up performance should register today for this informative webinar to learn how integrating the ambr platforms with single-use production scale bioreactors can help deliver high quality biologics rapidly and cost-effectively.”
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”
Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,700 people, and in 2014 earned sales revenue of 683.5 million euros.
A profile of WuXi Biologics
WuXi Biologics, a WuXi AppTec company, is a leading open-access technology capability and technology platform to enable anyone and any company to develop biologics. As a premier Contract Discovery, Development and Manufacturing Organization (CDMO), WuXi Biologics provides our worldwide clients with the necessary expertise, quality and capacities to develop biologic drugs from concept to commercialization. Along with our WuXi PharmaTech affiliates, we provide the world with the ONE true single-source approach that saves our clients critical time and money. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics’ services, please visit: http://www.wuxibiologics.com.
Cambridge, UK – September 28, 2016: Sartorius Stedim Biotech (SSB) today announced that it is co-presenting a new bioprocess webinar with WuXi Biologics, a premier Contract Discovery, Development and Manufacturing Organization, on Thursday 20th October. Two live events (at 09.00 GMT and 15.00 GMT) will include detail how WuXi Biologics is using ambr® micro and mini bioreactor platforms to accelerate bioprocess development of biologics in production scale single-use bioreactors.
During the live one-hour webinar, Dr Barney Zoro, ambr 15 Product Manager at SSB, will provide a brief overview of the ambr® 15 cell culture and ambr® 250 high throughput bioreactor systems and will explain how these can integrate seamlessly with the single-use BIOSTAT® STR manufacturing scale single-use bioreactors.
Dr Jincai Li, Vice-President at Wuxi Biologics, will detail their new single-use bioprocess development workflow. He will highlight how the ambr 15 system delivers better clone selection and feeding/product quality studies, as well as powerful Design of Experiment (DoE) optimization. Dr Li will also discuss how the ambr 250 high throughput system demonstrates excellent correlation to benchtop bioreactors with viable cell counts, titers and metabolite profiles, and will show how the ambr platforms are helping Wuxi Biologics’ scientists reduce time-lines when scaling up their bioprocesses into single-use bioreactors.
To join the webinar and receive a recording to listen to on-demand, scientists should register at: http://view6.workcast.net/register?cpak=2367672989355948
Dr Barney Zoro, ambr 15 Product Manager, at SSB commented: "I am pleased to be presenting a webinar with Dr Li, where he will show data on how WuXi Biologics’ new workflow supports increased experimental capacity to reduce timelines.”
Zoro added: “Scientists wanting to improve clone selection and accurately predict scale-up performance should register today for this informative webinar to learn how integrating the ambr platforms with single-use production scale bioreactors can help deliver high quality biologics rapidly and cost-effectively.”
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”
Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,700 people, and in 2014 earned sales revenue of 683.5 million euros.
A profile of WuXi Biologics
WuXi Biologics, a WuXi AppTec company, is a leading open-access technology capability and technology platform to enable anyone and any company to develop biologics. As a premier Contract Discovery, Development and Manufacturing Organization (CDMO), WuXi Biologics provides our worldwide clients with the necessary expertise, quality and capacities to develop biologic drugs from concept to commercialization. Along with our WuXi PharmaTech affiliates, we provide the world with the ONE true single-source approach that saves our clients critical time and money. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics’ services, please visit: http://www.wuxibiologics.com.